DNA repair genes were also assessed for pathogenic variants, and were defined as: BRCA1, BRCA2, ATM, BRIP1, CHEK2, NBN, MSH6, PMS2, RAD50, PALB2, and FANCA as per prior studies. 5 Fisher's exact test (with correction for false-discovery) was used to evaluate the association between DNA repair gene pathogenic variants with personal history/family history (as indicated by ICD-10 codes) and
Gleason score (which was abstracted from test request forms). Race, age at diagnosis, and stage information was not available through claims codes and were not systematically entered on test request forms. All analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, NC).
| RESULTS
As of August 2017, de-identified genetic test results were available from 1328 men with ICD-10 codes indicating a personal diagnosis of PCA. Family history of breast cancer was reported most commonly (n = 453), followed by family history of PCA (n = 369) and family history of GI cancers (n = 299). Among 898 men with Gleason score information available, 6.2% had a Gleason score >= 8.
Overall rate of pathogenic variants was 15.6% and rate of VUS was 37.2%. Overall rate of pathogenic variants in DNA repair genes was 10.9%. Pathogenic variant rates by genes tested is depicted in Figure 1 .
BRCA2 pathogenic variants were the most commonly identified (4.5%),
followed by pathogenic variants in CHEK2 (2.2%), ATM (1.8%), BRCA1
and RAD51D (0.1%). 15 Therefore, the impact of cascade testing among unaffected male BRCA carriers is expected to increase with evolving screening strategies.
The overall rate of VUS in our analysis was 37.2%, which is comparable to prior studies in the multigene testing setting. 6, 19 Since approximately a third of men with PCA undergoing multigene testing will have a VUS identified, urologists, and oncologists need to develop competency with understanding these results to accurately discuss VUS findings and potential future reclassification of results with patients. 20, 21 Finally, our "real-world" data analysis may also provide biologic leads into PCA predisposition or progression. Family history data were derived from ICD-10 codes and may be incomplete. Therefore "not reported" may not be equivalent to "no family history."
The use of a single lab as a data source is also a consideration.
There is known inter-lab variability of variant pathogenicity designation which could impact rates of pathogenic variants and VUS reported here. Additional factors may also influence results, such as differences in genetic testing practices between providers, patients tested, use of specific laboratories, or panel utilization. Thus, our results need to be confirmed for generalizability.
Since prior data have shown that PCA patients with metastatic disease have higher rates of germline DNA repair pathogenic variants which can inform therapy such as PARP inhibitors, 4,5 an additional consideration is that advanced cases may have made up a significant proportion of our dataset leading to uncharacterized selection bias.
Furthermore, genetic testing was performed prior to expansion of NCCN guidelines to include broad family history beyond cancers linked with HBOC. 1 Updated analyses in the era of expanded genetic testing guidelines will be needed.
| CONCLUSION
Our report includes one of the largest sample sets of "real-world"
genetic testing data to inform strategies for identification of men for genetic evaluation for inherited PCA. As genetic testing for men with PCA increases, provider education for urologists and oncologists regarding genetic results interpretation and family history-based recommendations for men with PCA and their families will be important to provide appropriate cancer genetic education and care delivery.
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